F. Joseph Halcomb III, MD Department of Biomedical Engineering, University of Kentucky, Lexington, KY, USA.
Department of Statistics, University of Kentucky, Lexington, KY, USA.
Osteoporos Int. 2019 Feb;30(2):277-285. doi: 10.1007/s00198-018-4760-x. Epub 2018 Nov 28.
Bone modulus from patients with osteoporosis treated with bisphosphonates for 1 to 20 years was analyzed. Modulus increases during the first 6 years of treatment and remains unchanged thereafter.
Bisphosphonates are widely used for treating osteoporosis, but the relationship between treatment duration and bone quality is unclear. Since material properties partially determine bone quality, the present study quantified the relationship between human bone modulus and hardness with bisphosphonate treatment duration.
Iliac crest bone samples from a consecutive case series of 86 osteoporotic Caucasian women continuously treated with oral bisphosphonates for 1.1-20 years were histologically evaluated to assess bone turnover and then tested using nanoindentation. Young's modulus and hardness were measured and related to bisphosphonate treatment duration by statistical modeling.
All bone samples had low bone turnover. Statistical models showed that with increasing bisphosphonate treatment duration, modulus and hardness increased, peaked, and plateaued. These models used quadratic terms to model modulus increases from 1 to 6 years of bisphosphonate treatment and linear terms to model modulus plateaus from 6 to 20 years of treatment. The treatment duration at which the quadratic-linear transition (join point) occurred also depended upon trabecular location. Hardness increased and peaked at 12.4 years of treatment; it remained constant for the next 7.6 years of treatment and was insensitive to trabecular location.
Bone modulus increases with bisphosphonate treatment durations up to 6 years, no additional modulus increases occurred after 6 years of treatment. Although hardness increased, peaked at 12.4 years and remained constant for the next 7.6 years of BP treatment, the clinical relevance of hardness remains unclear.
分析了接受双磷酸盐治疗 1 至 20 年的骨质疏松症患者的骨模量。治疗的前 6 年内骨模量增加,此后保持不变。
双磷酸盐被广泛用于治疗骨质疏松症,但治疗持续时间与骨质量之间的关系尚不清楚。由于材料性能部分决定了骨质量,因此本研究定量研究了人类骨模量与硬度与双磷酸盐治疗持续时间之间的关系。
对连续的 86 例骨质疏松症白种女性的髂嵴骨样本进行了组织学评估,以评估骨转换,然后使用纳米压痕法进行了测试。测量了杨氏模量和硬度,并通过统计模型将其与双磷酸盐治疗持续时间相关联。
所有骨样本的骨转换均较低。统计模型表明,随着双磷酸盐治疗持续时间的增加,模量和硬度增加,达到峰值并趋于平稳。这些模型使用二次项来模拟双磷酸盐治疗 1 至 6 年内的模量增加,使用线性项来模拟双磷酸盐治疗 6 至 20 年内的模量平稳。二次线性过渡(连接点)发生的治疗持续时间也取决于小梁的位置。硬度在治疗 12.4 年内增加并达到峰值;在接下来的 7.6 年内保持不变,并且对小梁位置不敏感。
骨模量随双磷酸盐治疗持续时间的增加而增加,治疗 6 年后骨模量不再增加。尽管硬度增加,在治疗 12.4 年内达到峰值并在接下来的 7.6 年内保持不变,但硬度的临床意义尚不清楚。